162 related articles for article (PubMed ID: 16756008)
1. [High-dose Roncoleukin in patients with disseminated cutaneous melanoma: a phase 1 study].
Moiseenko VM; Novik AV; Orlova RV; Protsenko SA; Mikhaĭlichenko TD; Semenova AI; Tiukavina NV
Vopr Onkol; 2005; 51(5):546-9. PubMed ID: 16756008
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
[TBL] [Abstract][Full Text] [Related]
3. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.
Davis ID; Skrumsager BK; Cebon J; Nicholaou T; Barlow JW; Moller NP; Skak K; Lundsgaard D; Frederiksen KS; Thygesen P; McArthur GA
Clin Cancer Res; 2007 Jun; 13(12):3630-6. PubMed ID: 17575227
[TBL] [Abstract][Full Text] [Related]
4. High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
Quan W; Ramirez M; Taylor WC; Vinogradov M; Khan N; Jackson S
Cancer Biother Radiopharm; 2004 Dec; 19(6):770-5. PubMed ID: 15665626
[TBL] [Abstract][Full Text] [Related]
5. Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2.
Esteban-González E; Carballido J; Navas V; Torregrosa Z; Muñoz A; de Mon MA;
Anticancer Drugs; 2007 Mar; 18(3):291-6. PubMed ID: 17264761
[TBL] [Abstract][Full Text] [Related]
6. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
Powell S; Dudek AZ
Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma.
Creagan ET; Ahmann DL; Long HJ; Frytak S; Sherwin SA; Chang MN
Cancer Treat Rep; 1987 Sep; 71(9):843-4. PubMed ID: 3113730
[TBL] [Abstract][Full Text] [Related]
8. Bolus high dose interleukin-2 for the treatment of malignant melanoma.
Pappo I; Lotem M; Klein M; Orda R
Isr Med Assoc J; 2001 Mar; 3(3):169-73. PubMed ID: 11303372
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
[TBL] [Abstract][Full Text] [Related]
10. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
[TBL] [Abstract][Full Text] [Related]
11. IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters.
Dorval T; Mathiot C; Chosidow O; Revuz J; Avril MF; Guillaume JC; Tursz T; Brandely M; Pouillart P; Fridman WH
Biotechnol Ther; 1992; 3(1-2):63-79. PubMed ID: 1305893
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
[TBL] [Abstract][Full Text] [Related]
13. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma.
Weide B; Derhovanessian E; Pflugfelder A; Eigentler TK; Radny P; Zelba H; Pföhler C; Pawelec G; Garbe C
Cancer; 2010 Sep; 116(17):4139-46. PubMed ID: 20564107
[TBL] [Abstract][Full Text] [Related]
14. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
Tarhini AA; Millward M; Mainwaring P; Kefford R; Logan T; Pavlick A; Kathman SJ; Laubscher KH; Dar MM; Kirkwood JM
Cancer; 2009 Feb; 115(4):859-68. PubMed ID: 19140204
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study.
Huland E; Burger A; Fleischer J; Fornara P; Hatzmann E; Heidenreich A; Heinzer H; Heynemann H; Hoffmann L; Hofmann R; Huland H; Kämpfer I; Kindler M; Kirchner H; Mehlhorn G; Moniak TH; Rebmann U; Roigas J; Schneider TH; Schnorr D; Schmitz HJ; Wenisch R; Varga Z; Vinke J
Folia Biol (Praha); 2003; 49(5):183-90. PubMed ID: 14680292
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
[TBL] [Abstract][Full Text] [Related]
17. Protracted vinblastine infusion. Phase I-II study in malignant melanoma and other tumors.
Lokich JJ; Zipoli TE; Perri J; Bothe A
Am J Clin Oncol; 1984 Oct; 7(5):551-3. PubMed ID: 6507377
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of metastatic malignant melanoma with interleukin-2].
Dorval T; Fridman WH; Mathiot C; Sastre X; Pouillart P
Bull Cancer; 1992; 79(8):781-7. PubMed ID: 1467601
[TBL] [Abstract][Full Text] [Related]
19. [Phase I clinical trial of intravenous recombinant human lymphotoxin-alpha derivative].
Wang FH; Li YH; Li S; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):501-4. PubMed ID: 16613689
[TBL] [Abstract][Full Text] [Related]
20. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Hofmann MA; Sterry W; Trefzer U
Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
